Page last updated: 2024-08-16

ribavirin and Body Weight

ribavirin has been researched along with Body Weight in 72 studies

Research

Studies (72)

TimeframeStudies, this research(%)All Research%
pre-19905 (6.94)18.7374
1990's2 (2.78)18.2507
2000's37 (51.39)29.6817
2010's26 (36.11)24.3611
2020's2 (2.78)2.80

Authors

AuthorsStudies
Cheng, ML; Li, H; Qin, YJ; Zhou, XN1
Dai, YL; Li, KW; Li, Y; Liang, YY; Niu, FJ; Wan, XH; Wang, YY; Wei, HC; Zhou, CZ1
Chen, Z; Li, GW; Wang, BL; Zhang, SJ1
Barrett, L; Bon, D; Chavez, J; Dewar, R; Fauci, AS; Fishbein, D; Gu, W; Herrmann, E; Heytens, L; Highbarger, H; Kleiner, D; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Polis, MA; Proschan, M; Shivakumar, B; Silk, R; Sneller, M; Subramanian, M; Symonds, WT; Talwani, R; Teferi, G; Wood, BJ; Wroblewski, S; Zhang, X1
Kawano, A; Miyagi, Y; Nomura, H; Tanimoto, H; Yamashita, N1
Buller, RM; Spencer, JF; Tollefson, AE; Toth, K; Wold, WS; Ying, B1
Anderson, PL; Baouchi-Mokrane, F; Burton, JR; D'Argenio, DZ; Everson, GT; Hammond, KP; Kiser, JJ; Rower, JE; Urban, TJ; Wu, LS1
Chang, JJ; Chien, CH; Chien, RN; Hu, CC; Lin, CL1
Besheer, M; El-Karaksy, HM; El-Raziky, MS; Mogahed, EA; Mubarak, S; Saleh, D1
Chen, DS; Chen, PJ; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Kao, JH; Liang, CC; Lin, CL; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Yang, HC; Yang, SS; Yu, ML1
Anzai, K; Eguchi, Y; Fujimoto, K; Iwane, S; Kawaguchi, Y; Kawazoe, S; Kuwashiro, T; Mizuta, T; Nakashita, S; Oeda, S; Otsuka, T; Oza, N; Ozaki, I; Takahashi, H1
Albrecht, JK; Alonso, E; Ciocca, M; Gonzalez, T; Goodman, Z; Haber, B; Jackson, B; Lacaille, F; Lang, T; Noviello, S; Pedreira, A; Rodriguez-Baez, N; Yang, Z1
Hamer, C1
Jiménez-Rivera, J; Marxuach-Cuétara, A; Ortiz-Lasanta, G; Purcell-Arevalo, D; Ríos-Bedoya, CF; Rodríguez-Torres, M1
Alsiö, A; Buhl, MR; Christensen, P; Dhillon, AP; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Leutscher, P; Mørch, K; Norkrans, G; Pedersen, C; Westin, J1
Anand, B; Barange, K; Diago, M; Govindarajan, S; Hooper, G; Lin, A; Morgan, T; Rodriguez-Torres, M; Shiffman, M; Suter, F1
Chuang, WL; Dai, CY; Huang, JF; Yu, ML1
Ichijo, T; Joshita, S; Kiyosawa, K; Komatsu, M; Matsumoto, A; Shirakawa, H; Tanaka, E; Tanaka, N; Umemura, T; Yoshizawa, K1
Ganslmayer, M; Hahn, EG; Herold, C; Zopf, S1
Ben-Ari, Z; Braun, M; Cohen, M; Cohen-Ezra, O; Katz, L; Manhaim, V; Rotman, Y; Tur-Kaspa, R1
Basso, M; Giannini, EG; Picciotto, A; Savarino, V1
Albrecht, JK; Alonso, E; Bortolotti, F; Brass, C; Broue, P; Calzado, MA; Ciocca, M; Galoppo, M; Gonzalez, T; Goodman, Z; Huber, WD; Hunter, B; Jara, P; Kerkar, N; Kullmer, U; Lacaille, F; Lachaux, A; Lang, T; Neigut, D; Noviello, S; Pedreira, A; Pollack, H; Ramakrishna, J; Ribes-Koninckx, C; Rodriguez-Baez, N; Shelton, M; Sniukiene, V; Valle-Segarra, AD; Wirth, S; Xu, CR; Zancan, L; Zheng, H1
Heathcote, EJ; Mazzulli, T; Pattullo, V; Ravindran, NC; Wong, DK1
Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Yu, ML1
Bacon, BR; Chun, E; Halliman, D; Hammond, J; Hassanein, T; Heise, J; Lawitz, E; Muir, AJ; Poordad, F; Shiffman, ML1
Abdurakhmanov, D; Bakulin, I; Cheinquer, H; Geyvandova, N; Harrison, SA; McKenna, M; Morozov, V; Rabbia, M; Reddy, KR; Rodriguez-Torres, M; Shiffman, ML; Silva, GF; Stanciu, C; Thommes, JA1
Ehleben, C; Pearlman, BL1
Chung, RT; Di Bisceglie, AM; Hassanein, T; Lentz, E; Poordad, FF; Prabhakar, A; Zhou, X1
Afdhal, N; Conjeevaram, HS; Everhart, JE; Hoofnagle, JH; Howell, CD; Wahed, AS1
Abu-Mouch, S; Buggisch, P; Chen, R; Cornberg, M; Faruqi, R; Hinrichsen, H; Horban, A; Ilan, Y; Klinker, H; Lurie, Y; Manns, M; Mauss, S; Merican, I; Müller, TH; Pedicone, LD; Rössle, M; Sood, A; Wedemeyer, H; Welsch, C; Zeuzem, S1
Chen, L; Dou, J; Guo, Q; Su, Z; Wang, H; Zhou, C; Zhou, H; Zhou, W1
Adinolfi, LE; Lonardo, A; Loria, P; Restivo, L; Zampino, R1
Baron, A; Brochot, E; Capron, D; Castelain, S; Coulouarn, C; Descamps, V; Duchaussoy, I; Duverlie, G; François, C; Nguyen-Khac, E1
Balistreri, W; Barton, BA; Duggan, C; Gonzalez-Peralta, RP; Haber, B; Jonas, MM; Lobritto, S; Mitchell, PD; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Rosenthal, P; Schwarz, KB; Shepherd, JA1
Abdurakhmanov, D; Bakulin, I; Cheinquer, H; Connell, EV; Harrison, SA; Mazur, W; McKenna, M; Messinger, D; Reddy, KR; Rodriguez-Torres, M; Shiffman, ML; Silva, GF; Tatsch, F1
Cai, L; Dowling, TC; Howell, CD; Jin, R; McHutchison, JG; Tan, M1
Jang, JY; Jeong, SW; Kim, BS; Kim, Hi; Kim, HS; Kim, SG; Kim, SH; Kim, YS; Lee, SW; Park, SS; Seo, YR; You, BC1
Hézode, C1
Friedlander, L; Kondaveeti, K; Van Thiel, DH1
Hrachovec, J; Patel, P1
Bailey, KW; Beadle, JR; Hostetler, KY; Sidwell, RW; Smee, DF; Wong, MH1
Dadgostari, S; Lin, CC; Vitarella, D; Xu, C; Yeh, LT1
Almasio, PL1
Bruno, R; Ciappina, V; Filice, G; Maiocchi, L; Patruno, S; Sacchi, P; Zocchetti, C1
Boyer, N; Cazals-Hatem, D; Consigny, Y; Degott, C; Marcellin, P; Marrache, F; Martinot, M; Ripault, MP; Valla, D1
D'Souza, UJ; Kumar, G; Narayan, P; Narayana, K1
Helbling, B; Mülhaupt, B; Telser, H; Zweifel, P1
Baczkowski, A; Geffner, M; González-Peralta, RP; Gupta, S; Haber, B; Jonas, MM; Kelly, DA; Lang, T; Laughlin, M; Lurie, Y; Martin, S; Mieli-Vergani, G; Molleston, J; Murray, KF; Shelton, M1
Kakizaki, S; Kanda, D; Mori, M; Sato, K; Sohara, N; Suzuki, H; Takagi, H1
Husa, P; Slesinger, P; Stroblová, H; Svobodník, A1
Bräu, N; Eldeiry, LS; Greenberg, PD; Naqvi, Z; Rosman, AS1
Alvarez, D; Ball, L; Brau, N; Dieterich, DT; Moorehead, L; Sulkowski, MS1
Chang, KC; Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Tseng, PL; Wang, JH; Yen, YH1
Brown, RS1
Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Gretch, DR; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Shiffman, ML; Wright, EC1
Araújo, E; Barone, AA; Borges, A; Coelho, HS; Corrêa-Giannella, ML; Ferraz, ML; Focaccia, R; Gonçales, FL; Gonçales, N; Lobato, C; Oliveira, U; Paixao, J; Perez, R; Rosa, H; Vigani, A; Vila, R; Weirich, J1
Damian, D; Gheorghe, C; Gheorghe, L; Grigorescu, M; Iacob, R; Iacob, S; Sirli, R; Sporea, I1
Han, SH; Smith, J1
Afdhal, N; Becker, S; Bernstein, D; Brass, CA; Brown, RS; Flamm, S; Freilich, B; Godofsky, E; Griffel, LH; Jacobson, IM; Kwo, PY; Mukhopadhyay, P; Pauly, MP; Pound, D; Santoro, J; Strauss, R; Wakil, AE1
Albert, C; Araya, V; Black, M; Brass, CA; Brown, RS; Dragutsky, MS; Freilich, B; Galler, GW; Griffel, LH; Hargrave, T; Harvey, J; Jacobson, IM; Kwo, PY; Lambiase, L; McCone, J; Siddiqui, FA1
Brown, RS; Jacobson, IM1
Canonico, PG; Cosgriff, TM; Donovan, JC; Kastello, MD; Ross, PE; Spears, CT; Stephen, EL1
Gupta, P; Patki, SA1
Ambrose, MW; Gilbert, BE; Meyerson, LR; Wyde, PR1
Bailey, KW; Sidwell, RW; Smee, DF1
Powell, J1
Cecil, BD1
Arensman, JB; Hilmas, DE; Tschorn, RR1
Divine, GW; Gilbert, BE; Knight, V; Yu, CP1
Craig, DK; Hoffmann, SH; Parker, G; Smith, RA; Staffa, JA1

Reviews

5 review(s) available for ribavirin and Body Weight

ArticleYear
Metabolic alterations and chronic hepatitis C: treatment strategies.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:14

    Topics: Antiviral Agents; Body Weight; Cholesterol; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-alpha; Metabolic Syndrome; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
Consensus conference. Treatment of hepatitis C.
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Adult; Aged; Alcoholism; Amantadine; Antiviral Agents; Body Weight; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Mental Disorders; Middle Aged; Monitoring, Physiologic; Quality of Life; Recurrence; Ribavirin; Risk Factors; Substance-Related Disorders; Time Factors

2002
[Treatment of patients with chronic hepatitis C who never had been treated].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Biopsy; Body Weight; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-2; Liver; Liver Cirrhosis; Meta-Analysis as Topic; Placebos; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Transaminases; Viral Load

2002
Weight-based dosing: which impact on efficacy and safety of therapy?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2004, Volume: 36 Suppl 3

    Topics: Antiviral Agents; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2004
Customizing treatment to patient populations.
    Nature clinical practice. Gastroenterology & hepatology, 2007, Volume: 4 Suppl 1

    Topics: Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Replication

2007

Trials

23 trial(s) available for ribavirin and Body Weight

ArticleYear
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
    JAMA, 2013, Aug-28, Volume: 310, Issue:8

    Topics: Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Prognosis; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load

2013
Weight loss during telaprevir-based triple therapy due to telaprevir-induced appetite loss.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:22

    Topics: Antiviral Agents; Appetite; Body Weight; Depression; Drug Therapy, Combination; Female; Genotype; Ghrelin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Ribavirin; Treatment Outcome; Weight Loss

2014
Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:4

    Topics: Adult; Antiviral Agents; Body Weight; Erythrocytes; Female; Half-Life; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Models, Statistical; Oligopeptides; Phosphorylation; Population; Ribavirin; Sex Characteristics

2015
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.
    Scientific reports, 2015, Oct-15, Volume: 5

    Topics: Adult; Aged; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2015
Impact of Body Weight Reduction via Diet and Exercise on the Anti-Viral Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Insulin Resistance: A Randomized Controlled Pilot Trial.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:24

    Topics: Adult; Antiviral Agents; Body Weight; Diet; Directive Counseling; Drug Therapy, Combination; Exercise; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Obesity; Pilot Projects; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Weight Loss

2015
Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection.
    Journal of pediatric gastroenterology and nutrition, 2017, Volume: 64, Issue:1

    Topics: Adolescent; Antiviral Agents; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; Growth Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2017
Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Mass Index; Body Surface Area; Body Weight; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Young Adult

2009
High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
    Journal of hepatology, 2010, Volume: 52, Issue:4

    Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child Development; Child, Preschool; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2010
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:4

    Topics: Adolescent; Adult; Anemia, Hemolytic; Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2010
Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
    Gastroenterology, 2010, Volume: 139, Issue:6

    Topics: Adult; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2010
Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:6

    Topics: Adolescent; Adult; Aged; Body Weight; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
    Journal of hepatology, 2011, Volume: 55, Issue:3

    Topics: Adult; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors

2011
Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:2

    Topics: Adolescent; Antiviral Agents; Body Composition; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Eating; Fatty Liver; Female; Growth Disorders; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Retreatment of high-dose interferon (5 MU daily) nonresponders with high-dose IFN + ribavirin.
    Digestive diseases and sciences, 2002, Volume: 47, Issue:9

    Topics: Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure

2002
Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C.
    Antiviral therapy, 2005, Volume: 10, Issue:2

    Topics: Antiviral Agents; Body Weight; Drug Carriers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:4

    Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; France; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2005
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
    Hepatology (Baltimore, Md.), 2005, Volume: 42, Issue:5

    Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2005
Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.
    World journal of gastroenterology, 2006, Feb-28, Volume: 12, Issue:8

    Topics: Adult; Aged; Anti-Ulcer Agents; Antiviral Agents; Body Weight; Carnosine; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Organometallic Compounds; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Zinc; Zinc Compounds

2006
Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:10

    Topics: Adult; Anemia; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Zidovudine

2006
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
    Gastroenterology, 2007, Volume: 132, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Time Factors

2007
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
    Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2007
Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.
    Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:4

    Topics: Antiviral Agents; Black or African American; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2007
Evaluation of ribavirin in the treatment of acute hepatitis.
    Chemotherapy, 1982, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Body Weight; Child; Clinical Trials as Topic; Double-Blind Method; Female; Hepatitis A; Humans; Male; Middle Aged; Ribavirin; Ribonucleosides

1982

Other Studies

44 other study(ies) available for ribavirin and Body Weight

ArticleYear
[A case of chronic hepatitis C treated with sofosbuvir/velpatasvir combined with ribavirin among 3-year-old children with low body weight].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023, Feb-20, Volume: 31, Issue:2

    Topics: Antiviral Agents; Body Weight; Child, Preschool; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Salvia plebeia R. Br. polysaccharides (SPP) against RSV (respiratory syncytial virus) infection: Antiviral effect and mechanisms of action.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 141

    Topics: Animals; Antiviral Agents; Body Weight; Cell Line; Cytokines; Eating; Humans; Lung; Mice; Mice, Inbred BALB C; Plant Extracts; Polysaccharides; Respiratory Function Tests; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Ribavirin; Salvia; Tetrazolium Salts; Thiazoles; Toll-Like Receptors

2021
Effect of the Haoqinqingdan decoction on damp-heat syndrome in rats with influenza viral pneumonia.
    Asian Pacific journal of tropical medicine, 2013, Volume: 6, Issue:8

    Topics: Animals; Antiviral Agents; Body Temperature; Body Weight; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fever; Flow Cytometry; Immunologic Factors; Interferon-gamma; Interleukin-4; Lymphocyte Subsets; Orthomyxoviridae Infections; Plant Extracts; Plants, Medicinal; Pneumonia, Viral; Rats; Rats, Wistar; Ribavirin; Treatment Outcome

2013
Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model.
    Antiviral research, 2014, Volume: 112

    Topics: Adenoviridae Infections; Adenoviruses, Human; Alanine Transaminase; Animals; Body Weight; Cell Line; Cidofovir; Cytosine; Disease Models, Animal; Female; Humans; Immunocompromised Host; Liver; Mesocricetus; Organophosphonates; Ribavirin; Survival Analysis; Treatment Outcome; Viral Load

2014
Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2015, Volume: 35, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Models, Biological; Ribavirin; Risk Factors; Treatment Outcome; Viral Load; Young Adult

2015
Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2016, Volume: 36, Issue:1

    Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Neutropenia; Neutrophils; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome; Viral Load

2016
The impact of combination therapy with peginterferon alpha-2a and ribavirin on the energy intake and body weight of adult hepatitis C patients.
    Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, 2008, Volume: 21, Issue:5

    Topics: Aged; Antiviral Agents; Appetite; Body Mass Index; Body Weight; Drug Therapy, Combination; Energy Intake; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires

2008
Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks.
    Journal of medical virology, 2008, Volume: 80, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome

2008
Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:2

    Topics: Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors

2008
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:2

    Topics: Age Factors; Body Weight; Fatty Liver; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2009
Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:3

    Topics: Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2008
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Mutation; Neutrophils; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells; Treatment Outcome; Viral Load; Young Adult

2008
Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation.
    Scandinavian journal of gastroenterology, 2009, Volume: 44, Issue:4

    Topics: Adult; Antiviral Agents; Body Weight; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin

2009
Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.
    Journal of internal medicine, 2009, Volume: 266, Issue:6

    Topics: Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2009
Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:12

    Topics: Antiviral Agents; Body Mass Index; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin doses.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:5

    Topics: Body Weight; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors

2010
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:4

    Topics: Antiviral Agents; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
    Gastroenterology, 2011, Volume: 140, Issue:2

    Topics: Adult; Age Factors; Antiviral Agents; Body Mass Index; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Synergistic activity of baicalein with ribavirin against influenza A (H1N1) virus infections in cell culture and in mice.
    Antiviral research, 2011, Volume: 91, Issue:3

    Topics: Administration, Oral; Animals; Antiviral Agents; Body Weight; Cell Culture Techniques; Cell Line; Dogs; Drug Combinations; Drug Synergism; Female; Flavanones; Influenza A Virus, H1N1 Subtype; Kidney; Lung; Mice; Mice, Inbred ICR; Orthomyxoviridae Infections; Ribavirin; Survival Rate; Viral Matrix Proteins; Virus Replication

2011
The treatment response of chronically hepatitis C virus-infected patients depends on interferon concentration but not on interferon gene expression in peripheral blood mononuclear cells.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2

    Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2012
Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
    Journal of clinical gastroenterology, 2013, Volume: 47, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult

2013
Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:11

    Topics: Antiviral Agents; Area Under Curve; Black or African American; Body Weight; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; White People

2012
A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.
    Clinical and molecular hepatology, 2012, Volume: 18, Issue:3

    Topics: Antiviral Agents; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome

2012
Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice.
    International journal of antimicrobial agents, 2004, Volume: 23, Issue:5

    Topics: Animals; Antiviral Agents; Body Weight; Brain; Cidofovir; Cytosine; Drug Evaluation, Preclinical; Heart; Liver; Lung; Mice; Mice, Inbred BALB C; Organophosphonates; Oxygen; Purines; Respiratory Tract Infections; Ribavirin; Salivary Glands; Spleen; Treatment Outcome; Vaccinia; Vaccinia virus; Viral Plaque Assay; Viremia

2004
[Hepatitis C infection. Overweight virus carriers are more difficult to cure].
    MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13

    Topics: Antiviral Agents; Biological Availability; Body Weight; Carrier State; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Metabolic Clearance Rate; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Viramidine demonstrates better safety than ribavirin in monkeys but not rats.
    Drug and chemical toxicology, 2004, Volume: 27, Issue:3

    Topics: Animals; Antiviral Agents; Area Under Curve; Blood Cell Count; Body Temperature; Body Weight; Eating; Electrocardiography; Eye Diseases; Female; Hemodynamics; Macaca fascicularis; Male; Organ Size; Rats; Rats, Sprague-Dawley; Respiratory Mechanics; Ribavirin

2004
The antiviral drug ribavirin reversibly affects the reproductive parameters in the male Wistar rat.
    Folia morphologica, 2005, Volume: 64, Issue:2

    Topics: Animals; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Genitalia, Male; Male; Organ Size; Rats; Rats, Wistar; Reproduction; Ribavirin; Spermatozoa; Testis; Testosterone

2005
[Cost comparison of two combination therapies with peginterferon alfa and ribavarin for the treatment of hepatitis C].
    Praxis, 2005, Aug-10, Volume: 94, Issue:32

    Topics: Algorithms; Antiviral Agents; Body Weight; Cost Savings; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
[The effect of patient's body weight, gender and baseline viral load on the efficacy of hepatitis C therapy].
    Vnitrni lekarstvi, 2006, Volume: 52, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; Viral Load

2006
Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:9

    Topics: Antiviral Agents; Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mellitus; Erythrocyte Indices; Female; Glycated Hemoglobin; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; L-Lactate Dehydrogenase; Male; Middle Aged; Reticulocyte Count; Retrospective Studies; Ribavirin

2006
Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response.
    Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:9

    Topics: Age Factors; Anemia; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Treatment Outcome

2006
Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2006, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2006
Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting.
    Journal of gastrointestinal and liver diseases : JGLD, 2007, Volume: 16, Issue:1

    Topics: Adult; Antiviral Agents; Body Weight; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2007
"True" weight-based dosing versus "flat" dosing of ribavirin: will the WIN-R please come forward?
    Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:4

    Topics: Antiviral Agents; Black or African American; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; White People

2007
WIN-R revisited: Response to editorial.
    Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:4

    Topics: Antiviral Agents; Black or African American; Body Weight; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Hematological and bone marrow effects of ribavirin in rhesus monkeys.
    Toxicology and applied pharmacology, 1984, Jun-30, Volume: 74, Issue:2

    Topics: Animals; Blood Cells; Body Weight; Bone Marrow; Erythrocyte Count; Erythrocyte Indices; Female; Hematocrit; Hemoglobins; Macaca mulatta; Male; Ribavirin; Ribonucleosides; Thrombocytosis

1984
The antiviral activity of SP-303, a natural polyphenolic polymer, against respiratory syncytial and parainfluenza type 3 viruses in cotton rats.
    Antiviral research, 1993, Volume: 20, Issue:2

    Topics: Animals; Antiviral Agents; Biopolymers; Body Weight; Catechin; Culture Techniques; Lung; Parainfluenza Virus 3, Human; Paramyxoviridae Infections; Plants, Medicinal; Respiratory Syncytial Viruses; Respirovirus Infections; Ribavirin; Sigmodontinae; Viral Plaque Assay

1993
Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir.
    Antiviral chemistry & chemotherapy, 2000, Volume: 11, Issue:4

    Topics: Animals; Antiviral Agents; Body Weight; Cell Line; Chlorocebus aethiops; Cidofovir; Cowpox; Cowpox virus; Cytosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Lung; Mice; Mice, Inbred BALB C; Organophosphonates; Organophosphorus Compounds; Respiratory Tract Infections; Ribavirin; Vero Cells; Viral Plaque Assay

2000
Treating hepatitis C: a clinician's perspective. Interview by Bob Roehr.
    Journal of the International Association of Physicians in AIDS Care, 1998, Volume: 4, Issue:7

    Topics: Antiviral Agents; Biopsy; Body Weight; Dose-Response Relationship, Drug; Hepatitis C; HIV Infections; Interferon Type I; Liver; Liver Transplantation; Recombinant Proteins; Ribavirin

1998
Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Lancet (London, England), 2002, Jan-19, Volume: 359, Issue:9302

    Topics: Antiviral Agents; Body Weight; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
Effect of small-particle aerosols of rimantadine and ribavirin on pathophysiologic changes associated with A/NJ influenza in mice.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1978, Volume: 158, Issue:3

    Topics: Adamantane; Aerosols; Animals; Antiviral Agents; Body Weight; Bridged-Ring Compounds; Female; Influenza A virus; Lung; Mice; Organ Size; Orthomyxoviridae Infections; Oxygen; Ribavirin; Ribonucleosides; Time Factors

1978
Estimating the dosage of ribavirin aerosol according to age and other variables.
    The Journal of infectious diseases, 1988, Volume: 158, Issue:2

    Topics: Adolescent; Adult; Aerosols; Age Factors; Body Weight; Bronchi; Child; Child, Preschool; Female; Fever; Humans; Infant; Intubation, Intratracheal; Lung; Male; Respiration; Ribavirin; Ribonucleosides; Sex Factors; Tidal Volume; Trachea

1988
Inhalation toxicity of ribavirin in suckling ferrets.
    Journal of applied toxicology : JAT, 1987, Volume: 7, Issue:5

    Topics: Administration, Inhalation; Animals; Animals, Suckling; Body Weight; Carnivora; Female; Ferrets; Organ Size; Particle Size; Pregnancy; Ribavirin; Ribonucleosides; Therapeutic Irrigation

1987